Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
10/23/2023 | — | TD Cowen | Downgrades | Outperform → Market Perform | |
08/16/2023 | 442.64% | Chardan Capital | $8 → $7 | Maintains | Buy |
08/15/2023 | 520.16% | Wedbush | → $8 | Reiterates | Outperform → Outperform |
08/01/2023 | 520.16% | Chardan Capital | → $8 | Reiterates | Buy → Buy |
06/26/2023 | 442.64% | Piper Sandler | $10 → $7 | Maintains | Overweight |
05/16/2023 | 520.16% | Chardan Capital | → $8 | Reiterates | Buy → Buy |
05/04/2023 | 558.91% | Cantor Fitzgerald | → $8.5 | Initiates Coverage On | → Buy |
05/03/2023 | 520.16% | Chardan Capital | $10 → $8 | Maintains | Buy |
03/31/2023 | 520.16% | TD Securities | $10 → $8 | Maintains | Outperform |
03/31/2023 | 520.16% | Baird | $7 → $8 | Maintains | Neutral |
02/28/2023 | 675.19% | Chardan Capital | → $10 | Reiterates | → Buy |
02/01/2023 | 442.64% | Citigroup | $7.5 → $7 | Maintains | Buy |
01/31/2023 | 675.19% | Chardan Capital | $13 → $10 | Maintains | Buy |
01/31/2023 | 442.64% | Baird | $8 → $7 | Maintains | Neutral |
01/25/2023 | 210.08% | Morgan Stanley | $7 → $4 | Downgrades | Equal-Weight → Underweight |
12/15/2022 | 481.4% | Citigroup | $8 → $7.5 | Maintains | Buy |
09/30/2022 | 442.64% | Morgan Stanley | $8 → $7 | Maintains | Equal-Weight |
09/15/2022 | 907.75% | Chardan Capital | $18 → $13 | Maintains | Buy |
09/15/2022 | 520.16% | Baird | $11 → $8 | Maintains | Neutral |
09/15/2022 | 675.19% | BMO Capital | $12 → $10 | Maintains | Outperform |
06/15/2022 | 675.19% | Cowen & Co. | $14 → $10 | Maintains | Outperform |
06/15/2022 | 752.71% | Baird | $9 → $11 | Maintains | Neutral |
06/03/2022 | 520.16% | Morgan Stanley | $10 → $8 | Maintains | Equal-Weight |
04/07/2022 | 675.19% | Citigroup | $11 → $10 | Maintains | Buy |
02/10/2022 | 675.19% | Morgan Stanley | → $10 | Downgrades | Overweight → Equal-Weight |
01/13/2022 | 1295.35% | Chardan Capital | $17 → $18 | Maintains | Buy |
11/23/2021 | 1217.83% | Chardan Capital | → $17 | Initiates Coverage On | → Buy |
09/22/2021 | 1062.79% | UBS | → $15 | Initiates Coverage On | → Buy |
09/20/2021 | 985.27% | Wedbush | → $14 | Initiates Coverage On | → Outperform |
09/14/2021 | 1062.79% | Morgan Stanley | → $15 | Initiates Coverage On | → Overweight |
09/10/2021 | 907.75% | BMO Capital | → $13 | Initiates Coverage On | → Outperform |
08/23/2021 | 752.71% | Baird | → $11 | Initiates Coverage On | → Neutral |
08/23/2021 | 1062.79% | Cowen & Co. | → $15 | Initiates Coverage On | → Outperform |
What is the target price for Li-Cycle Holdings (LICY)?
The latest price target for Li-Cycle Holdings (NYSE: LICY) was reported by TD Cowen on October 23, 2023. The analyst firm set a price target for $0.00 expecting LICY to fall to within 12 months (a possible -100.00% downside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Li-Cycle Holdings (LICY)?
The latest analyst rating for Li-Cycle Holdings (NYSE: LICY) was provided by TD Cowen, and Li-Cycle Holdings downgraded their market perform rating.
When is the next analyst rating going to be posted or updated for Li-Cycle Holdings (LICY)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Li-Cycle Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Li-Cycle Holdings was filed on October 23, 2023 so you should expect the next rating to be made available sometime around October 23, 2024.
Is the Analyst Rating Li-Cycle Holdings (LICY) correct?
While ratings are subjective and will change, the latest Li-Cycle Holdings (LICY) rating was a downgraded with a price target of $0.00 to $0.00. The current price Li-Cycle Holdings (LICY) is trading at is $1.29, which is out of the analyst's predicted range.